Electroconvulsive therapy (ECT), also known as electroshock, is a well-established, albeit controversial, psychiatric treatment in which seizures are electrically induced in anesthetized patients for therapeutic effect. Today, ECT is most often used as a treatment for severe major depression which has not responded to other treatment, and is also used in the treatment of mania (often in bipolar disorder), and catatonia. It was first introduced in the 1930s and gained widespread use as a form of treatment in the 1940s and 1950s; today, an estimated 1 million people worldwide receive ECT every year, usually in a course of 6-12 treatments administered 2 or 3 times a week.
mood episodes for treatment-resistant patients. There are no reports of metabolic syndromes associated with ECT. Moss and Vaidya (1) reviewed the charts of 10 patients who have received MECT at their institution over the last 10-year period.
Five of 10 patients were obese pre-ECT, all of whom had a significant weight loss after ECT. Patients whose weights were normal pre-ECT, did not experience weight loss. These finding suggests that ECT is a viable alternative for overweight patients with mood disorders who do not respond to mood stabilizers or cannot tolerate side effects.
Electroconvulsive therapy as treatment for obese mice
It has been previously suggested that low affinity [3H]mazindol binding in the hypothalamus correlates with body weight and obesity. Low affinity [3H]mazindol binding in hypothalamic crude synaptosome preparations was carried out in normoglycemic obese mice (C57 B1/6J ob/ob) as well as in their lean littermates (C57 B1/6J +/?). NIH Swiss mice were used as additional controls. Furthermore the effect on this binding site of repeated electroconvulsive shock (ECS), a treatment known to change body weight gain, was studied in rats. Neither Bmax nor Kd were altered in obese mice compared with their lean littermates or NIH Swiss mice. The obese mice had a significantly greater body weight and weight gain than either control group. Once-daily ECS over 10 days (which significantly reduced weight gain in rats) did not change binding parameters for [3H]mazindol in hypothalami. The present data do not appear to support the hypothesis that this low affinity binding site has a physiological function in the control of body weight and obesity, at least in the examined paradigm (2) . 
The hypothalamus and the regulation of energy homeostasis
The hypothalamus is the focus of many peripheral signals and neural pathways that control energy homeostasis and body weight. Emphasis has moved away from anatomical concepts of 'feeding' and 'satiety' centres to the specific neurotransmitters that modulate feeding behaviour and energy expenditure. regulated by fasting and hypoglycaemia. The LHA is important in receiving sensory signals from the gut and liver, and in sensing glucose, and orexin neurones may be involved in stimulating feeding in response to falls in plasma glucose.
Depression and Obesity
Recent evidence suggests that neuronal plasticity plays an important role in the recovery from depression. Antidepressant drugs and electroconvulsive shock treatment increase the expression of several molecules, which are associated with neuronal plasticity, in particular the neurotrophin BDNF and its receptor TrkB.
Furthermore, these treatments increase neurogenesis and synaptic numbers in several brain areas. Conversely, depression, at least in its severe form, is associated with reduced volumes of the hippocampus and prefrontal cortex and in at least some cases these neurodegenerative signs can be attenuated by successful treatment. Such observations suggest a central role for neuronal plasticity in depression and the antidepressant effect, and also implicate BDNF signaling as a mediator of this plasticity. The antidepressant fluoxetine can reactivate developmental-like neuronal plasticity in the adult visual cortex, which, under appropriate environmental guidance, leads to the rewiring of a developmentally dysfunctional neural network. These observations suggest that the simple form of the neurotrophic hypothesis of depression, namely, that deficient levels of neurotrophic support underlies mood disorders and increases in these neurotrophic factors to normal levels brings about mood recovery, may not sufficiently explain the complex process of recovery from depression (5) .
Anesthesia for Electroconvulsive therapy in obese patients
Kadar et al. (6) described obese patients who have successfully undergone over 650 consecutive uncomplicated ECT treatments without any special precautions at two major U.S. medical centers. All of these patients were fasted overnight and breathed 100% oxygen using a face mask before induction of anesthesia with methohexital 60-120 mg IV. After loss of consciousness, succinylcholine, 40-120 mg IV, was administered for muscle relaxation. Ventilation was assisted using positive pressure with a face mask until the patient was able to resume adequate spontaneous respirations. The ECT procedures were performed in the supine position with their upper body elevated 15-30 degrees. All patients recovered without any adverse incidents and were discharged from the recovery area within one hour after completing the ECT treatment. There were no cases of aspiration (as assessed clinically) in over 650 consecutive general anesthetics for ECT in this obese population, including 97 consecutive procedures in 9 morbidly obese (Class III) patients.
Conclusion
A new treatment for obesity is suggested based on unnoticed information from only two articles in which " Five of 10 patients were obese pre-ECT, all of whom had a 6 significant weight loss after ECT" and " Once-daily ECS over 10 days (which significantly reduced weight gain in rats)".
Further studies are needed in order to evaluate this hypothesis.
